One of the main challenges is the difficulty in conducting large-scale clinical trials due to the small patient population. Additionally, there is often a lack of awareness and understanding about rare cancers within both the medical community and the general public. Funding is another significant hurdle, as rare cancers do not attract the same level of financial support as more common cancers.
